Xiling Lab Pharmaceutical Co., Ltd.is a new drug R & D company based in China and operating globally. Driven by innovation and cooperation, it provides safe and effective innovative drugs for patients in China and the world.
Xiling Lab Pharmaceutical Co., Ltd. was established in August 2016, owns Chengdu kelingyuan Pharmaceutical Technology Co., Ltd. and Guixi PharmaTech Pty Ltd. in Australia. Xiling Lab has the qualification of "national high tech enterprise", and its core technology and management team have been awarded the title of "top innovation and entrepreneurship team" in Sichuan Province and Chengdu City.
Xiling Lab is committed to building an internationally leading platform for small molecule drug concept validation, contrast agent drug development and catalytic technology. The company emphasizes practical innovation. At present, it has applied for more than 20 invention patents, of which 3 have completed the transfer of development rights, which has achieved considerable economic benefits for the company
Since its establishment, based on the concept of "win-win cooperation", the company has established partnership with a number of domestic and foreign biomedical enterprises to create a "global new" innovative drug product pipeline and "characteristic" series of contrast agent products. Among them, smp-100 for the treatment of irritable bowel syndrome has obtained the FDA clinical trial license, and is in the process of carrying out I-I in Australia A number of contrast media products have been verified and entered the application stage.
Record of events
Business Affairs：email@example.comContact us